Fractyl Health, Inc. Common Stock

Fractyl Health, Inc. Common Stock Q3 2026 Earnings Recap

GUTS Q3 2026 Published November 14, 2026

Get alerts when GUTS reports next quarter

Set up alerts — free

Fractyl Health rose 11.3% after reporting that REMAIN-1 met its six-month co-primary endpoint, supporting the potential of Revita to help patients maintain weight loss after stopping tirzepatide. The result is encouraging, but the 12-month endpoint remains unreported and is expected in Q1 2027.

Earnings Per Share Beat
$-1.07 vs $-1.50 est.
+28.7% surprise

Market Reaction

Post-Earnings +11.27%

See GUTS alongside your other holdings

Add to your portfolio — free

Key Takeaways

  • In REMAIN-1, participants lost an average of 18.3% of body weight on tirzepatide before stopping treatment; 308 participants were included in the modified intention-to-treat population.
  • At six months, Revita participants retained about 80% of their prior weight loss; the co-primary endpoint was met with a p-value of 0.0023.
  • Management reported that the separation from sham widened from months 1 to 6. A post hoc analysis found the best-performing patients, treated over roughly 20 centimeters or more, had less than half the weight regain of sham.
  • One in three Revita participants were weight-stable or had lost more weight six months after stopping tirzepatide, and nearly half retained at least 80% of their weight loss.
  • The company reported no device- or procedure-related serious adverse events, deaths, or unanticipated adverse device effects. The formal 12-month endpoint is expected in Q1 2027; management also said a de novo application is planned later this quarter.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GUTS on AllInvestView.

Get the Full Picture on GUTS

Track Fractyl Health, Inc. Common Stock in your portfolio with real-time analytics, dividend tracking, and more.

View GUTS Analysis